Intravesical CD74 and CXCR4, macrophage migration inhibitory factor (MIF) receptors, mediate bladder pain.
<h4>Background</h4>Activation of intravesical protease activated receptor 4 (PAR4) leads to release of urothelial macrophage migration inhibitory factor (MIF). MIF then binds to urothelial MIF receptors to release urothelial high mobility group box-1 (HMGB1) and elicit bladder hyperalges...
Saved in:
Main Authors: | Shaojing Ye, Fei Ma, Dlovan F D Mahmood, Katherine L Meyer-Siegler, Raymond E Menard, David E Hunt, Lin Leng, Richard Bucala, Pedro L Vera |
---|---|
Format: | article |
Language: | EN |
Published: |
Public Library of Science (PLoS)
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/7fc27f72d7f44943824ab56be9a0a3f1 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficient intravesical therapy of bladder cancer with cationic doxorubicin nanoassemblies
by: Jin X, et al.
Published: (2016) -
Increased serum levels of macrophage migration inhibitory factor (MIF) in patients with microscopic polyangiitis
by: Hirohito Kanemitsu, et al.
Published: (2009) -
Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review
by: Mi Ah Han, et al.
Published: (2021) -
Role of the Macrophage Migration Inhibitory Factor (MIF) in the survival of first trimester human placenta under induced stress conditions
by: Francesca Ietta, et al.
Published: (2018) -
Magnetic multiwalled carbon nanotubes with controlled release of epirubicin: an intravesical instillation system for bladder cancer
by: Suo N, et al.
Published: (2019)